362049-48-7
362049-48-7
Chemical Structure
Tryptamine-d2 hydrochloride
- CAS No.: 362049-48-7
- Formula:C10H11D2ClN2
- Molecular Weight:198.69
IUPAC Name: 2-(1H-indol-3-yl)ethan-1,1-d2-1-amine hydrochloride
InChIKey: KDFBGNBTTMPNIG-GZEMNZGQSA-N
SMILES: NC([2H])([2H])CC1=CNC2=CC=CC=C12.[H]Cl
Biological Activity: Tryptamine-d2 (hydrochloride) is a deuterium labeled Tryptamine hydrochloride. Tryptamine hydrochloride is a monoamine alkaloid, similar to other trace amines, is believed to play a role as a neuromodulator or neurotransmitter[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tryptamine-d2 hydrochloride | Tryptamine-d2 (hydrochloride) is a deuterium labeled Tryptamine hydrochloride. Tryptamine hydrochloride is a monoamine alkaloid, similar to other trace amines, is believed to play a role as a neuromodulator or neurotransmitter. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tryptamine (Standard) | 97.84% | Tryptamine (Standard) is the analytical standard of Tryptamine. This product is intended for research and analytical applications. Tryptamine is a monoamine alkaloid, similar to other trace amines, is believed to play a role as a neuromodulator or neurotransmitter. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tryptamine | 99.89% | Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs) and accelerates gastrointestinal motility. Tryptamine regulates Th17/Treg balance to inhibit neuroinflammation, competitively binds to 5-HT receptors to regulate central nervous system activity, and participates in temperature regulation and spinal reflex regulation as a neuromodulator. Tryptamine can be used to study intestinal motility disorders such as functional constipation, and has shown significant efficacy in multiple sclerosis models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
